FAQs – On Narcotic Drugs, Brand Names of drug (G.S.R. no. 828 (E) dated 06.11.2019) etc.

1668
FAQs
Picture: Pixabay
Lalit Kr. Goel

Last Updated on July 18, 2021 by The Health Master

FAQs – On Narcotic Drugs, Brand Names of drug (G.S.R. no. 828 (E) dated 06.11.2019) etc.

FAQ
Picture: Pixabay

Q1:   Who issues permission for manufacturing of Narcotic drugs?

Ans:  Excise and Taxation department issues permission on Form 24 to the manufacturer on the recommendation of State Drugs Controller.

Q2:   Who issues permission for sale to the chemist shops for sale of Narcotic drugs?

Ans:  Excise and Taxation department issues permission on Form 25 to the chemist shop on the recommendation of State Drugs Controller.

Q3:   Whether the nursing homes required license for stocking Narcotic drugs?

Ans:  Yes, RMI (Registered Medical Institute) certificate issued by State Drugs Controller in which six drugs has been notified which come under this certificate.

Also read More FAQs, click here

Q4:   What are the new guidelines regarding Brand Name permissions to the manufacture for allopathic drugs?

Ans:  As per Govt. notification no. 828(E) dated 06.11.2019, the allopathic drug manufacturer if wants to manufacture drugs by brand name then he should submit Form-51 to the concerned State Drug Controller.

To download the notification, click here

Q5:   Is any fee / challan form required for taking permission?

Ans:  No. If the firm is already having permission of the drug in generic then there is no need of extra fee.

Q6:   What is the status of Tramadol salt?

Ans:  This drug comes under NDPS Act as psychotropic substances on dated 26.04.2018.

Q7:   What is status of combination of Buprenorphine+Naloxone sublingual tablets?

Ans:  These tablets are covered under NDPS Act, official in USP 2018. This preparation can be supplied to psychiatric clinics and hospitals in addition to de-addiction centres as per latest DCG(I)’s letter dated 28.03.2019.


To read all FAQs of the author, click here


Subscribe for daily free updates

Telegram
WhatsApp
Facebook
LinkedIn

Enter your email address:

Delivered by FeedBurner